Classic
Quiz Sciences

Quiz 2

18 played - 13 yrs ago

You have 10 minutes

 

Hard QUIZ 10 QUESTIONS
hard
1

'This supplemental new drug application provides for the use TAXOTERE in combination with cisplatin for the treatment of ... . . What should we select as generic or innovator type for this case?

2
What should we select as generic or innovator type for Photrex according to info given?

What should we select as generic or innovator type for Photrex according to info given?

3
What should we select as generic or innovator type for APD515 and APD515 Topical, respectively?

What should we select as generic or innovator type for APD515 and APD515 Topical, respectively?

4
Assume that there is a news telling us that Photrex is approved. What should we select as generic or innovator type for Photrex?

Assume that there is a news telling us that Photrex is approved. What should we select as generic or innovator type for Photrex?

5
Assume that there is a news telling us that Photrex is approved. What should we select as generic or innovator type for MV2101?

Assume that there is a news telling us that Photrex is approved. What should we select as generic or innovator type for MV2101?

6
What should we select as generic or innovator type for above product? (Hint. CYC202 is a non-approved product)

What should we select as generic or innovator type for above product? (Hint. CYC202 is a non-approved product)

7
How many of the rows given are incorrect?

How many of the rows given are incorrect?

8

Molecule X was only approved in Japan previously and the company is developing a new product, ABC-103, using that molecule in the USA. What should we select as type for ABC-103 in this case?

9

'Compound X is an intraocular, polymer implant containing human retinal epithelial cells genetically modified to continually deliver... ' What should we select as type for Compound X?

10

Compound X is a subcutaneous formulation which is on market. You have a news telling that intramuscular formulation of the product is approved later on. In this case, ... ...